HIV Infections Clinical Trial
Official title:
New Orleans AIDS Task Force Adopting and Demonstrating the Adaptation of Prevention Techniques (ADAPT) With Popular Opinion Leader (POL)
Adopting and Demonstrating the Adaptation of Prevention Techniques (ADAPT) is a supplement
to the Centers for Disease Control and Prevention (CDC) Community Based Organization Program
Announcement 04064 (PA 04064). The purpose of ADAPT is to improve the understanding of the
processes needed for adapting evidence-based behavioral interventions to fit new conditions
or populations and to pilot the CDC-developed adaptation guidance. The ADAPT project
responds to concerns from the field that existing interventions do not address the HIV
prevention needs of their specific population. This project seeks to develop guidance for
agencies to engage in the evidence-based adaptation of interventions previously shown to be
effective in evaluation settings for use in real world applications.
The New Orleans AIDS Task Force (NO/AIDS) is one of five grantees funded to use the
adaptation guidance to adapt an intervention packaged by the CDC's Replicating Effective
Programs and disseminated by CDC's Diffusion of Effective Behavioral Interventions. The
agency will adapt Jeff Kelly's Popular Opinion Leader (POL) intervention (Kelly, 2004; Kelly
et al., 1991) for use in Internet venues with seropositive men who identify
ethnically/racially as other than White/Caucasian who have sex with other men (men who have
sex with men [MSM] of color).
Kelly's POL intervention is a community-level, evidence-based HIV prevention intervention
that originally targeted gay and bisexual men in smaller cities throughout the United
States. Kelly's intervention seeks to identify and enlist the support of well-known and
well-liked opinion leaders to take on risk reduction advocacy roles. Opinion leaders attend
sessions to learn how to engage in risk reduction conversations with people in their own
social networks. The opinion leaders help to reshape social norms to encourage safer sex by
helping to create a social environment in which MSM feel comfortable and empowered to make
decisions to avoid high-risk sexual behaviors.
Status | Completed |
Enrollment | 27 |
Est. completion date | January 2009 |
Est. primary completion date | September 2007 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Seropositive - Men who have sex with other men - African American - At least 18 years of age - Report having sexual contact with a man (any type of sexual contact in which either partner achieved orgasm) within the last year - Those who frequent viable venues for recruiting pre-and post-implementation questionnaire respondents Exclusion Criteria: - MSM who are not willing to identify themselves to study staff as seropositive Hispanic MSM may be excluded. - Those under 18 years of age will be excluded from participation due to the study design precluding direct applicability of hypotheses and intervention to both adults and children due to different cognitive development, HIV prevalence levels, and social networks. - Serious mental illness which makes the individual unsuitable for participation - Under the influence of drugs or alcohol which makes the individual unsuitable for participation - Anyone who does not meet the inclusion criteria |
Time Perspective: Retrospective
Country | Name | City | State |
---|---|---|---|
United States | New Orleans AIDS Task Force | New Orleans | Louisiana |
Lead Sponsor | Collaborator |
---|---|
Centers for Disease Control and Prevention |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Qualitative data collected during online focus groups to discuss risky sexual behavior engaged in by men who have sex with men (MSM) of color and access online venues primarily frequented by MSM in the New Orleans LA area. | Fall/winter 2006 | No | |
Secondary | Development of Popular Opinion Leader behavioral HIV prevention intervention materials adapted for use online use with men who have sex with men (MSM) of color and who access online venues primarily frequented by MSM in the New Orleans LA area. | Spring 2007 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |